Helius Medical Technologies Inc Class A (HSDT) Stock Forecast & Price Target
Helius Medical Technologies Inc Class A · NASDAQ
$2.24+0.00 (+0.00%)
15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Helius Medical Technologies Inc Class A, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $3.50 to $4.00, so the covering firms are broadly aligned. The average target of $3.75 sits 67% above the current $2.24. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 1 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.03 next quarter toward $-0.02 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Strong Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Helius Medical Technologies Inc Class A.
As of Sep, 2 of 2 firms rate HSDT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
HSDT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.03
Range $-0.03 – $-0.03 · 1 analysts
Next period, 1 analysts expect Helius Medical Technologies Inc Class A to earn $-0.03 a share (range $-0.03 – $-0.03), versus — a year earlier. Full-year consensus is $-1.71, growing to $-0.02 the year after.
REVENUE · NEXT QUARTER
$2.7M
Range $2.7M – $2.7M · 1 analysts
Revenue is expected to reach $2.7M (range $2.7M – $2.7M). Full-year consensus is $11.4M, rising to $11.0M next year.
Top analysts covering Helius Medical Technologies Inc Class A
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on HSDT.
#1
Anthony Vendetti
Maxim Group · Rank #335
Hold
No targeton HSDT
Overall win rate
30%
+ Follow
#2
Matthew Galinko
Maxim Group · Rank #435
Buy
$4.00+78.6% to target
Overall win rate
24%
+ Follow
#3
FS
Fedor Shabalin
B. Riley Securities
Buy
$3.50+56.2% to target
Coverage
—
+ Follow
HSDT stock forecast FAQ
What is HSDT's average 12-month price target?+
The 2 analysts with a live target average $3.75 for Helius Medical Technologies Inc Class A over the next 12 months, ranging from a $4.00 high to a $3.50 low.
Is HSDT stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for HSDT?+
The Street-high target is $4.00 (Maxim Group), and the Street-low is $3.50 (B. Riley Securities). The average of all 2 active targets is $3.75.
How many Wall Street analysts cover HSDT?+
2 analysts have an active rating on Helius Medical Technologies Inc Class A, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering HSDT?+
Among analysts who currently cover HSDT, Anthony Vendetti of Maxim Group has the strongest overall Quantellect track record (Rank #335). Their current call is Hold.
What is Helius Medical Technologies Inc Class A's projected EPS for next quarter?+
The consensus estimate is $-0.03 per share (range $-0.03 – $-0.03) across 1 analysts. Full-year EPS is projected at $-1.71, rising to $-0.02 the following year.
How much revenue is Helius Medical Technologies Inc Class A expected to report next quarter?+
Consensus revenue is $2.7M (range $2.7M – $2.7M). Full-year revenue is projected at $11.4M, growing to $11.0M next year.
Have analysts been upgrading or downgrading HSDT lately?+
As of Sep, 2 of 2 firms rate HSDT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their HSDT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
